When Protection Becomes a Problem
Research published in the Journal of Biological Chemistry, led by USC professor Kelvin J. A. Davies, highlights a paradox at the heart of NRF2 biology: the same protective pathway that shields healthy cells from oxidative damage can also help cancer cells survive treatment.
Typically, oxidative stress is something to be avoided — the antioxidant industry is a multi-billion dollar enterprise built on this principle. Oxidative stress has been linked to over 200 diseases. But in cancer treatment, oxidative stress is actually the weapon: both radiation therapy and many chemotherapy drugs work by overwhelming cancer cells with free radicals.
How Cancer Hijacks NRF2
Professor Davies demonstrated that cancer cells can upregulate NRF2 to produce "survival enzymes" that neutralize the very oxidative damage that radiation and chemotherapy are designed to inflict. This means:
- Cancer cells with high NRF2 activity can survive doses of radiation that should kill them
- Chemotherapy drugs that work through oxidative mechanisms become less effective
- Tumors can develop treatment resistance over time as NRF2 activity increases
This phenomenon is explored in detail in our article on the dual role of NRF2 in cancer.
The NRF2 Paradox in Cancer
NRF2's role in cancer is genuinely dual-natured:
The Protective Side (Before Cancer)
- NRF2 prevents DNA mutations that could initiate cancer
- NRF2 detoxifies carcinogens before they can damage cells
- NRF2 promotes the repair of DNA damage
- NRF2 supports immune surveillance against precancerous cells
The Dark Side (After Cancer Develops)
- Cancer cells can constitutively activate NRF2 through mutations
- High NRF2 protects cancer cells from treatment-induced death
- NRF2-driven metabolic changes fuel cancer cell growth
- Drug-resistance genes are upregulated by NRF2 in tumors
Direct vs. Indirect Antioxidants
The Davies research raises an important distinction. The genes expressed by the body's cells through NRF2 activation are far more effective at reducing oxidative stress than eating foods containing direct antioxidants (like vitamin C or vitamin E). This means NRF2 activation has a more powerful impact on cellular defense — for better or worse.
For healthy individuals, this makes NRF2 activation overwhelmingly beneficial. For cancer patients undergoing treatment, however, the equation is more complex.
What This Means for Cancer Patients
If you are undergoing radiation or chemotherapy:
- Always consult your oncologist before taking any NRF2-activating supplements
- Some oncologists may recommend avoiding high-dose antioxidant supplements during active treatment
- Dietary intake of NRF2-activating foods at normal levels is generally considered safe — discuss with your care team
- NRF2 activation may be beneficial before and after cancer treatment to protect healthy tissues
The Future: NRF2 Inhibitors for Cancer
Researchers are now developing NRF2 inhibitors that could be administered alongside chemotherapy to strip cancer cells of their oxidative defenses. This approach — suppressing NRF2 specifically in tumor cells while maintaining it in healthy tissue — represents a promising new frontier in cancer treatment.
References
- Davies KJA, et al. "Nrf2 signaling and the response of cancer cells to oxidative stress." Journal of Biological Chemistry. University of Southern California.
- Jaramillo MC, Zhang DD. "The emerging role of the Nrf2-Keap1 signaling pathway in cancer." Genes Dev. 2013;27(20):2179-91.